Check out the Detailed Program! Learn More

Updates on the Lyon Consensus for GERD Diagnosis

The Lyon Consensus established a structured way to diagnose gastroesophageal reflux disease (GERD) when symptoms alone cannot provide a reliable answer. Its central contribution was to distinguish objective evidence of reflux from symptom-based impressions, helping clinicians avoid both overdiagnosis and missed disease.

Since the original 2018 document, expert discussions have refined how acid exposure, reflux monitoring, endoscopy, and adjunctive tests should be interpreted. These developments are particularly relevant for patients with persistent symptoms, normal endoscopy, or an incomplete response to proton pump inhibitors.

The subject also fits the educational mission of the International Society for Diseases of the Esophagus. The ISDE 2021 congress brought together specialists in esophageal disorders through scientific sessions, workshops, presentations, and research exchange, offering a valuable setting for examining evolving diagnostic standards.

Why The Consensus Matters

GERD can present with heartburn and regurgitation, but similar complaints may arise from functional heartburn, reflux hypersensitivity, achalasia, eosinophilic esophagitis, or other upper gastrointestinal conditions. A symptom response to medication may support a clinical impression, yet it does not independently prove pathological reflux.

The Lyon framework therefore emphasizes a hierarchy of evidence. Conclusive findings, such as severe reflux esophagitis, long-segment Barrett’s esophagus, or clearly abnormal reflux monitoring, carry greater diagnostic weight than nonspecific symptoms. This approach supports individualized testing rather than routine treatment escalation.

Strong And Supportive Evidence

In the updated interpretation of the consensus, conclusive evidence includes Los Angeles grade C or D esophagitis, a peptic stricture, or long-segment Barrett’s esophagus. When these findings are present, the probability of GERD is high and additional testing may not be necessary before treatment.

Ambulatory reflux monitoring provides another important route to confirmation. Acid exposure time above the accepted abnormal threshold, especially when consistently elevated across monitoring, is considered strong evidence. Total reflux episodes, symptom association, and the mean nocturnal baseline impedance can add context, but they should not be interpreted in isolation.

What Lyon 2.0 Adds

Lyon 2.0, published after the original consensus, gives greater attention to borderline results and the need to combine multiple data points. An acid exposure time below 4% generally argues against pathological GERD, while a value above 6% supports the diagnosis. Results between these ranges require clinical judgment and additional evidence.

The newer framework also recognizes that reflux burden can vary. Patients with inconclusive acid exposure may benefit from reviewing reflux episode counts, symptom association probability, post-reflux swallow-induced peristaltic wave measurements, and impedance-derived markers. These tests are most useful when integrated with endoscopy, manometry, and the patient’s treatment history.

Diagnostic finding Interpretation Typical next step
Severe erosive esophagitis or peptic stricture Conclusive evidence of GERD Begin or optimize treatment; further confirmation may be unnecessary
Acid exposure time above 6% Strong evidence of pathological reflux Correlate with symptoms and plan long-term management
Acid exposure time below 4% Evidence against GERD in many cases Investigate functional or alternative causes
Acid exposure time between 4% and 6% Inconclusive range Combine impedance, symptom association, and clinical findings
Normal endoscopy with persistent symptoms GERD remains unconfirmed Consider reflux monitoring off or on therapy, depending on the clinical question

Testing Before And During Treatment

The choice of reflux test depends on whether GERD has already been established. For patients without conclusive endoscopic evidence, monitoring off proton pump inhibitors can determine whether abnormal reflux exists. Wireless pH monitoring may extend observation over several days, while catheter-based pH-impedance testing measures both acid and non-acid reflux.

For patients with proven GERD who remain symptomatic while taking medication, pH-impedance monitoring on therapy can assess ongoing reflux and symptom correlation. This distinction matters because testing off treatment asks whether GERD exists, whereas testing on treatment asks whether symptoms reflect persistent reflux despite therapy.

High-resolution manometry does not diagnose GERD directly, but it helps exclude major motility disorders and identifies the esophagogastric junction anatomy. It is also important before antireflux surgery or selected endoscopic procedures.

Symptoms, Hypersensitivity, And Mimics

A positive symptom association between reflux events and reported complaints can support reflux hypersensitivity, even when total acid exposure is normal. Conversely, a lack of association weakens the case that reflux is causing symptoms. Accurate symptom logging during ambulatory monitoring is therefore essential.

Persistent throat clearing, cough, chest discomfort, or globus should be assessed carefully rather than automatically labeled as extraesophageal GERD. These symptoms often have multiple causes, and evidence for empiric acid suppression is less consistent than it is for typical heartburn or regurgitation.

Applying Evidence In Clinical Practice

A practical diagnostic pathway should match the test to the uncertainty:

  • Use endoscopy to identify mucosal injury, Barrett’s esophagus, stricture, or alternative disease.
  • Perform reflux monitoring off therapy when GERD has not been objectively established.
  • Use pH-impedance monitoring on therapy for persistent symptoms in patients with confirmed GERD.
  • Interpret borderline acid exposure with supportive metrics rather than a single threshold.
  • Consider manometry when symptoms suggest a motility disorder or an invasive antireflux treatment is being evaluated.

Education remains central to applying these recommendations consistently. Specialists, trainees, and researchers can review the congress’s educational resources and registration information as part of the broader ISDE program focused on esophageal disease.

The Lyon Consensus has moved GERD diagnosis toward a more evidence-based model: confirm disease when possible, recognize uncertainty when it exists, and avoid treating every upper gastrointestinal symptom as acid reflux. Explore the ISDE 2021 scientific content to deepen your understanding of reflux monitoring, esophageal physiology, and modern diagnostic decision-making.

About ISDE

The ISDE is an international, multispecialty society devoted to the study of the esophagus in disease and in health that was founded in 1979. The aims of the ISDE are to promote the exchange of scientific and medical knowledge among specialists in the field, to maintain interchange with organizations and industries, and to encourage basic and clinical research in fields related to the esophagus. In order to promote the professional and educational development of individuals interested in the esophagus, the ISDE sponsors its own journal, international congresses, and other educational programs. The ISDE Secretariat was in Tokyo, Japan, from 1979 to 2004, and then resided in Los Angeles, California, from 2004 through 2010. Since 2010 the Secretariat has been in Vancouver, British Columbia, under the auspices of International Conferences Service, Ltd. The ISDE welcomes participation by existing members and encourages individuals who are professionally interested in the esophagus to become members. Benefits include reduced registration fees at our congresses and other educational offerings, restricted access to website content and member search capability, access to webcasts, reduced subscription rates for our journal, and the opportunity to help lead this organization into a position of leadership in the worldwide medical community.